Clinical Trial Update: Venetoclax+HMA+Aclarubicin Versus Venetoclax+HMA in Treatment-Naive Elderly Patients With AML [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing venetoclax plus hypomethylating agent plus aclarubicin versus venetoclax plus HMA in treatment-naive elderly patients with acute myelo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Aclarubicin (aclarubicin)
• Hypomethylating agent
• Venetoclax (venetoclax)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Acute Myeloid Leukemia | Phase 3 | Status: UNKNOWN